<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Agenus Inc — News on 6ix</title>
<link>https://6ix.com/company/agenus-inc</link>
<description>Latest news and press releases for Agenus Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 17 Apr 2026 20:43:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/agenus-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683543be78dffbe2df0e1d84.webp</url>
<title>Agenus Inc</title>
<link>https://6ix.com/company/agenus-inc</link>
</image>
<item>
<title>Agenus Reports Phase II Data Demonstrating Immune Reprogramming and Durable Survival with Botensilimab, Balstilimab and agenT-797 in PD-1 Refractory Gastroesophageal Cancer</title>
<link>https://6ix.com/company/agenus-inc/news/agenus-reports-phase-ii-data-demonstrating-immune-reprogramming-and-durable-survival-with-botensilimab-balstilimab-and-agent-797-in-pd-1-refractory-gastroesophageal-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/agenus-inc/news/agenus-reports-phase-ii-data-demonstrating-immune-reprogramming-and-durable-survival-with-botensilimab-balstilimab-and-agent-797-in-pd-1-refractory-gastroesophageal-cancer</guid>
<pubDate>Fri, 17 Apr 2026 20:43:00 GMT</pubDate>
<description>LEXINGTON, Mass., April 17, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced data from an investigator-initiated Phase II trial at Memorial Sloan Kettering Cancer Center, investigating botensilimab (BOT) and balstilimab (BAL) in combination with agenT-797, MiNK’s allo-iNKT cell therapy, ramucirumab and paclitaxel in patients with advanced PD-1 refractory gastroesophageal adenocarcinoma. The data are being presented at the American Association for Cancer R</description>
</item>
<item>
<title>Agenus Announces Data from Phase II Study of BOT+BAL in Combination with agent-797 in PD-1 Refractory Gastroesophageal Cancer to be Presented at AACR 2026</title>
<link>https://6ix.com/company/agenus-inc/news/agenus-announces-data-from-phase-ii-study-of-botbal-in-combination-with-agent-797-in-pd-1-refractory-gastroesophageal-cancer-to-be-presented-at-aacr-2026</link>
<guid isPermaLink="true">https://6ix.com/company/agenus-inc/news/agenus-announces-data-from-phase-ii-study-of-botbal-in-combination-with-agent-797-in-pd-1-refractory-gastroesophageal-cancer-to-be-presented-at-aacr-2026</guid>
<pubDate>Fri, 03 Apr 2026 04:00:00 GMT</pubDate>
<description>Study highlights novel multi-mechanistic immunotherapy combination in checkpoint-refractory disease Data expected to inform immune modulation, treatment</description>
</item>
<item>
<title>Agenus Announces First Patient Enrolled in Global Phase 3 BATTMAN Trial of BOT+BAL Immunotherapy Combination in MSS or pMMR Metastatic Colorectal Cancer</title>
<link>https://6ix.com/company/agenus-inc/news/agenus-announces-first-patient-enrolled-in-global-phase-3-battman-trial-of-botbal-immunotherapy-combination-in-mss-or-pmmr-metastatic-colorectal-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/agenus-inc/news/agenus-announces-first-patient-enrolled-in-global-phase-3-battman-trial-of-botbal-immunotherapy-combination-in-mss-or-pmmr-metastatic-colorectal-cancer</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>A Landmark Registrational Study Aiming to Redefine Outcomes in MSS mCRC Which Represents Approximately 95% of Metastatic Colorectal Cancer Cases Colorectal</description>
</item>
<item>
<title>Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access</title>
<link>https://6ix.com/company/agenus-inc/news/agenus-to-host-march-2026-stakeholder-webcast-harnessing-the-immune-system-to-advance-bot-bal-across-tumor-types-and-expand-patient-access</link>
<guid isPermaLink="true">https://6ix.com/company/agenus-inc/news/agenus-to-host-march-2026-stakeholder-webcast-harnessing-the-immune-system-to-advance-bot-bal-across-tumor-types-and-expand-patient-access</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>Webcast on Tuesday, March 31, 2026, at 4:30 p.m. ET LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology,</description>
</item>
<item>
<title>Agenus Announces Upcoming AACR 2026 Presentation Evaluating Botensilimab Plus Balstilimab in First-Line MSS Metastatic Colorectal Cancer</title>
<link>https://6ix.com/company/agenus-inc/news/agenus-announces-upcoming-aacr-2026-presentation-evaluating-botensilimab-plus-balstilimab-in-first-line-mss-metastatic-colorectal-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/agenus-inc/news/agenus-announces-upcoming-aacr-2026-presentation-evaluating-botensilimab-plus-balstilimab-in-first-line-mss-metastatic-colorectal-cancer</guid>
<pubDate>Tue, 17 Mar 2026 04:00:00 GMT</pubDate>
<description>A novel, chemo-sparing strategy (BBoPCO): introducing BOT+BAL in 1L MSS mCRC to extend survival and reduce use of cytotoxic chemotherapy LEXINGTON,</description>
</item>
<item>
<title>Agenus Reports 2025 Results; BOT+BAL Advances to Phase 3 and Early Access Programs Expand Globally with Initial Revenues Recognized</title>
<link>https://6ix.com/company/agenus-inc/news/agenus-reports-2025-results-botbal-advances-to-phase-3-and-early-access-programs-expand-globally-with-initial-revenues-recognized</link>
<guid isPermaLink="true">https://6ix.com/company/agenus-inc/news/agenus-reports-2025-results-botbal-advances-to-phase-3-and-early-access-programs-expand-globally-with-initial-revenues-recognized</guid>
<pubDate>Mon, 16 Mar 2026 04:00:00 GMT</pubDate>
<description>Early access programs expand globally: 200+ physician inquiries across 30+ countries; $4.2M in initial program revenue recognized CRC leads BOT+BAL clinical</description>
</item>
<item>
<title>Agenus Triggers First $20M Contingent Payment Under Zydus Life Sciences Collaboration to Support BOT+BAL Manufacturing Needs</title>
<link>https://6ix.com/company/agenus-inc/news/agenus-triggers-first-dollar20m-contingent-payment-under-zydus-life-sciences-collaboration-to-support-botbal-manufacturing-needs-4</link>
<guid isPermaLink="true">https://6ix.com/company/agenus-inc/news/agenus-triggers-first-dollar20m-contingent-payment-under-zydus-life-sciences-collaboration-to-support-botbal-manufacturing-needs-4</guid>
<pubDate>Tue, 10 Mar 2026 04:00:00 GMT</pubDate>
<description>Work orders for key CMC and production activities activate first contingent payment as global demand expands across clinical and paid compassionate access</description>
</item>
<item>
<title>Agenus to Provide Fourth Quarter and Year-end 2025 Financial Report and Corporate Update</title>
<link>https://6ix.com/company/agenus-inc/news/agenus-to-provide-fourth-quarter-and-year-end-2025-financial-report-and-corporate-update-57</link>
<guid isPermaLink="true">https://6ix.com/company/agenus-inc/news/agenus-to-provide-fourth-quarter-and-year-end-2025-financial-report-and-corporate-update-57</guid>
<pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
<description>LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its</description>
</item>
<item>
<title>Agenus Presents Biomarker Data Demonstrating Survival Stratification in MSS mCRC and Other Immunologically Cold Tumors Treated with BOT+BAL</title>
<link>https://6ix.com/company/agenus-inc/news/agenus-presents-biomarker-data-demonstrating-survival-stratification-in-mss-mcrc-and-other-immunologically-cold-tumors-treated-with-botbal</link>
<guid isPermaLink="true">https://6ix.com/company/agenus-inc/news/agenus-presents-biomarker-data-demonstrating-survival-stratification-in-mss-mcrc-and-other-immunologically-cold-tumors-treated-with-botbal</guid>
<pubDate>Thu, 19 Feb 2026 20:15:00 GMT</pubDate>
<description>LEXINGTON, Mass., February 19, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced new translational and clinical biomarker data from its Phase 1b C-800-01 trial (NCT03860272) evaluating botensilimab (BOT), an Fc-enhanced anti–CTLA-4 antibody, in combination with balstilimab (BAL), an anti–PD-1 antibody. The data were presented today at the American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference in Los Angeles.</description>
</item>
<item>
<title>Agenus to Present New Data at AACR-IO Exploring Systemic and Tumor Inflammation Biomarkers with BOT/BAL in Immunologically Cold Tumors</title>
<link>https://6ix.com/company/agenus-inc/news/agenus-present-data-aacr-io-180000147</link>
<guid isPermaLink="true">https://6ix.com/company/agenus-inc/news/agenus-present-data-aacr-io-180000147</guid>
<pubDate>Mon, 09 Feb 2026 18:00:00 GMT</pubDate>
<description>LEXINGTON, Mass., February 09, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that new translational and clinical biomarker analyses from its botensilimab (BOT) immunotherapy program have been accepted for poster presentation at the American Association for Cancer Research- Immuno-Oncology (AACR-IO) Conference, taking place in Los Angeles, CA on February 18–21, 2026.</description>
</item>
<item>
<title>Agenus Expands Medical Affairs Infrastructure to Support Increasing Physician Requests for Authorized Access to Botensilimab Plus Balstilimab</title>
<link>https://6ix.com/company/agenus-inc/news/agenus-expands-medical-affairs-infrastructure-123000155</link>
<guid isPermaLink="true">https://6ix.com/company/agenus-inc/news/agenus-expands-medical-affairs-infrastructure-123000155</guid>
<pubDate>Wed, 21 Jan 2026 12:30:00 GMT</pubDate>
<description>LEXINGTON, Mass., January 21, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the expansion of its global Medical Affairs infrastructure and early-access support capabilities in response to increasing physician-initiated interest regarding authorized access to the investigational immunotherapy combination botensilimab plus balstilimab (BOT+BAL).</description>
</item>
<item>
<title>Agenus to Host First 2026 Stakeholder Webcast</title>
<link>https://6ix.com/company/agenus-inc/news/agenus-host-first-2026-stakeholder-232400888</link>
<guid isPermaLink="true">https://6ix.com/company/agenus-inc/news/agenus-host-first-2026-stakeholder-232400888</guid>
<pubDate>Tue, 20 Jan 2026 23:24:00 GMT</pubDate>
<description>LEXINGTON, Mass., January 20, 2026--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its first Stakeholder Webcast of 2026, Access to Acceleration: Agenus’ Global Momentum Entering 2026 on Wednesday, January 28, 2026, at 4:00 p.m. ET.</description>
</item>
<item>
<title>Agenus Announces Closing of $141M Strategic Collaboration with Zydus Lifesciences to Advance BOT+BAL and Strengthen U.S. Manufacturing Readiness</title>
<link>https://6ix.com/company/agenus-inc/news/agenus-announces-closing-141m-strategic-120100208</link>
<guid isPermaLink="true">https://6ix.com/company/agenus-inc/news/agenus-announces-closing-141m-strategic-120100208</guid>
<pubDate>Thu, 15 Jan 2026 12:01:00 GMT</pubDate>
<description>LEXINGTON, Mass., January 15, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the closing of its previously disclosed strategic collaboration with Zydus Lifesciences Ltd. The agreement is designed to accelerate global development and potential commercialization of Agenus’ botensilimab and balstilimab (BOT+BAL) immunotherapy combination program.</description>
</item>
<item>
<title>France Expands National AAC Access for Agenus' Botensilimab + Balstilimab for Ovarian Cancer and Soft-Tissue Sarcomas</title>
<link>https://6ix.com/company/agenus-inc/news/france-expands-national-aac-access-123000356</link>
<guid isPermaLink="true">https://6ix.com/company/agenus-inc/news/france-expands-national-aac-access-123000356</guid>
<pubDate>Mon, 12 Jan 2026 12:30:00 GMT</pubDate>
<description>LEXINGTON, Mass., January 12, 2026--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that France’s National Agency for Medicines and Health Products Safety (ANSM) has approved an updated national treatment protocol for botensilimab (BOT) plus balstilimab (BAL) under France’s Autorisation d’Accès Compassionnel (AAC) framework.</description>
</item>
<item>
<title>Agenus Reports Deep, Durable Responses with Botensilimab + Balstilimab in Highly Refractory Ovarian Cancer, Published in JITC</title>
<link>https://6ix.com/company/agenus-inc/news/agenus-reports-deep-durable-responses-130500112</link>
<guid isPermaLink="true">https://6ix.com/company/agenus-inc/news/agenus-reports-deep-durable-responses-130500112</guid>
<pubDate>Tue, 23 Dec 2025 13:05:00 GMT</pubDate>
<description>LEXINGTON, Mass., December 23, 2025--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the publication of clinical results from the ovarian cancer cohort of its Phase 1b C-800-01 trial evaluating botensilimab plus balstilimab (BOT+BAL) in The Journal for ImmunoTherapy of Cancer (JITC).</description>
</item>
<item>
<title>Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL</title>
<link>https://6ix.com/company/agenus-inc/news/agenus-host-end-stakeholder-webcast-210100587</link>
<guid isPermaLink="true">https://6ix.com/company/agenus-inc/news/agenus-host-end-stakeholder-webcast-210100587</guid>
<pubDate>Wed, 19 Nov 2025 21:01:00 GMT</pubDate>
<description>LEXINGTON, Mass., November 19, 2025--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its End-of-Year 2025 Stakeholder Webcast on Wednesday, December 3, 2025 at 4:00 p.m. ET. The session will feature leading experts in gastrointestinal oncology and patient advocates discussing progress with the BOT/BAL program, emerging clinical insights, and the evolving treatment landscape for colorectal cancer.</description>
</item>
<item>
<title>Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France’s AAC</title>
<link>https://6ix.com/company/agenus-inc/news/agenus-appoints-dr-jos-iglesias-134100437</link>
<guid isPermaLink="true">https://6ix.com/company/agenus-inc/news/agenus-appoints-dr-jos-iglesias-134100437</guid>
<pubDate>Tue, 18 Nov 2025 13:41:00 GMT</pubDate>
<description>LEXINGTON, Mass., November 18, 2025--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the appointment of José Iglesias, M.D. as Chief Medical Affairs Officer, effective November 10, 2025. Dr. Iglesias will lead global medical affairs for botensilimab (BOT) and balstilimab (BAL) as the combination advances through Phase 3 evaluation and becomes available in selected countries through early-access mechanisms, including France’s Autorisation d’Accès Compassionnel</description>
</item>
<item>
<title>Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances</title>
<link>https://6ix.com/company/agenus-inc/news/agenus-reports-q3-2025-results-123000535</link>
<guid isPermaLink="true">https://6ix.com/company/agenus-inc/news/agenus-reports-q3-2025-results-123000535</guid>
<pubDate>Mon, 10 Nov 2025 12:30:00 GMT</pubDate>
<description>LEXINGTON, Mass., November 10, 2025--Agenus Inc. (Nasdaq: AGEN) today reported quarterly results for the period ended September 30, 2025, and provided a business update. Highlights include government‑funded, reimbursed compassionate access (AAC) in France for botensilimab plus balstilimab (BOT/BAL), new survival data presented at ESMO and ESMO‑GI across more than 400 patients spanning more than five refractory cancers, and initiation of the global Phase 3 BATTMAN trial.</description>
</item>
<item>
<title>Agenus to Provide Corporate Update and Third Quarter 2025 Financial Report</title>
<link>https://6ix.com/company/agenus-inc/news/agenus-corporate-third-quarter-2025-184700758</link>
<guid isPermaLink="true">https://6ix.com/company/agenus-inc/news/agenus-corporate-third-quarter-2025-184700758</guid>
<pubDate>Wed, 05 Nov 2025 18:47:00 GMT</pubDate>
<description>LEXINGTON, Mass., November 05, 2025--Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in immuno-oncology, today announced that the Company will release its third quarter 2025 financial results before the market opens on Monday, November 10, 2025.</description>
</item>
<item>
<title>Agenus Reports 39% of Patients Alive at Two-Years with BOT/BAL Across Multiple Refractory Solid Tumors at ESMO 2025</title>
<link>https://6ix.com/company/agenus-inc/news/agenus-reports-39-patients-alive-120000982</link>
<guid isPermaLink="true">https://6ix.com/company/agenus-inc/news/agenus-reports-39-patients-alive-120000982</guid>
<pubDate>Fri, 17 Oct 2025 12:00:00 GMT</pubDate>
<description>LEXINGTON, Mass., October 17, 2025--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced new data from its botensilimab (BOT), a multifunctional, Fc-enhanced CTLA-4 antibody and balstilimab (BAL), a PD-1 inhibitor, combination demonstrating durable survival across multiple cancer types in late-stage patients who have limited treatment options. The results, featured in an oral session at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin, Germa</description>
</item>
</channel>
</rss>